

# SOLTI

**Country:** Spain

**Group:** Grupo Espanol de Estudio Tratamiento y otras Estrategias Experimentales en Tumores Solidos (**SOLTI**)

---

**Chair:** Dr H. Cortes-Funes MD, PhD

**Chairman of Scientific Committee:** Dr J. Baselga, MD, PhD

**Website:** [www.gruposolti.org](http://www.gruposolti.org)

**Title:** A phase III randomized, controlled trial of myocet, trastuzumab and paclitaxel *versus* trastuzumab and paclitaxel for first line therapy of metastatic breast cancer.

**Coordinator(s):** J. Baselga MD, PhD


**Summary:** Final Protocol Released in January 2006

- The target accrual is 600 randomized patients, 300 in each Arm

**Objective:**

- The primary objectives of this trial are to demonstrate the efficacy and cardiac safety of Myocet when given in combination with trastuzumab and paclitaxel in patients with HER2+ metastatic breast cancer.

**Scheme:**



**Update:** • Clinical Trial Submission in March 2006.

**Related Publications:** None available

**Topics:**

- Anthracyclines
- Cardiac function
- HER2 positive patients
- Metastatic breast cancer
- Taxanes
- Trastuzumab

**Keywords:** Myocet HER2 positive patients, metastatic breast cancer, doxorubicin, trastuzumab